Skip to main content
Signal8

PMGC Holdings Inc. (ELAB)

PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions. Its flagship product, EL-22, is a pioneering engineered probiotic designed to tackle the critical challenge of maintaining muscle mass during weight reduction regimens, especially those utilizing GLP-1 receptor agonists. Beyond its core operations, the company also engages in medical scientific research and development and manages various investment firms. Formerly known as Elevai Labs, Inc., the organization adopted its current name, PMGC Holdings Inc., in December 2024. Established in 2020, PMGC Holdings Inc. maintains its headquarters in Newport Beach, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

PMGC Holdings Inc. logo

PMGC Holdings Inc.

NASDAQ:ELABHealthcare
AH+1.35%$1.50
Close$1.48-10.84%
Mkt Cap$1.73M
EV-
Float1.17M
O/S1.17M
VOL159K sh
$ Vol$248K
RVOL0.22×
Inst Own1.7%
SI1.6%
Net Cash/Sh-
Dilution
PMGC Holdings Inc. logoNASDAQ:ELABAH$1.50+1.35%
Clinical Trials

No clinical trials found

Trials are sourced from ClinicalTrials.gov based on sponsor name matching.